Gilead Sciences

Gilead Sciences

Founded in 1987 in Foster City, California, Gilead Sciences operates as a large-cap biopharmaceutical company with a product portfolio dominating HIV treatment and prevention, alongside carve-outs in viral hepatitis and cell therapy for cancer. The company reports more than 17,000 employees across six continents and runs its primary R&D and commercial operations from its headquarters at 333 Lakeside Drive. Gilead's revenue base is anchored by long-cycle antiviral therapies, creating durable cash flows that fund both internal drug development and external acquisitions. The firm's allocation of capital flows through three therapeutic areas: virology, oncology, and inflammation. Its virology franchise, centered on HIV medicines offered globally, provides the commercial backbone. The oncology division is built around Kite Pharma, acquired in 2017 for approximately $11.9 billion, which brought chimeric antigen receptor T-cell therapy Trodelvy and a cell therapy manufacturing infrastructure into the fold. Gilead directs resources toward clinical programs spanning these three areas, with a disclosed pipeline that emphasizes late-stage assets and label expansion opportunities rather than discovery-phase risk. Gilead's operational scale is defined by its 17,000-person workforce distributed across 35-plus countries. The company maintains distinct corporate functions: a corporate development team handling M&A and partnership transactions, an investor relations apparatus managing public-market stakeholders, and a corporate giving program alongside the Gilead Foundation, which funds philanthropic HIV initiatives in the United States. The firm's supplier-inclusion program and product-quality complaint systems reflect a vertically integrated operational structure uncommon among pure-play biotech firms of smaller scale. Gilead's structural differentiator lies in its dual identity as both an operating pharmaceutical company and a capital allocator executing large-scale M&A to replenish its pipeline. Unlike biotech platforms that rely heavily on discovery-stage science, Gilead deploys cash flows from its HIV franchise into bolt-on acquisitions and clinical program advancement, a model that concentrates risk in execution rather than early-stage experimentation. The company's cell therapy subsidiary, Kite, operates with separate public affairs and clinical inquiry channels, suggesting a deliberate organizational separation that preserves focus within each therapeutic unit.